Background No single clinical or biologic marker reliably predicts clinical outcomes in acute
lung injury (ALI)/ARDS. We hypothesized that a combination of biologic and clinical markers
would be superior to either biomarkers or clinical factors alone in predicting ALI/ARDS
mortality and would provide insight into the pathogenesis of clinical ALI/ARDS. Methods
Eight biologic markers that reflect endothelial and epithelial injury, inflammation, and
coagulation (von Willebrand factor antigen, surfactant protein D [SP-D]), tumor necrosis …